Antigenic variations in the CD4 induced sites of the CCR5-tropic, pathogenic SHIVSF162P3 gp120 variants

被引:12
作者
Hsu, M
Buckner, C
Harouse, J
Gettie, A
Blanchard, J
Robinson, JE
Chen-Mayer, C
机构
[1] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
[2] Tulane Natl Primate Res Ctr, Covington, LA USA
[3] Tulane Univ, Ctr Hlth Sci, New Orleans, LA USA
关键词
antigenicity; CCR5; clones; envelope; SHIV;
D O I
10.1034/j.1600-0684.2003.00027.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
In vivo passage of non-pathogenic, CCR5-tropic simian/human immunodeficiency virus (SHIV) - SHIVSF162 resulted in a pathogenic isolate, SHIVSF162P3. In an attempt to characterize envelope (Env)-mediated properties that may contribute to its pathogenicity, major (P3 major) and minor (P3 minor) Env gp120 variants were cloned from the plasma of a SHIVSF162P3-infected animal, and expressed in the context of luciferase reporter viruses. Entry mediated by these envelopes and susceptibility to neutralization by CD4 induced-site (CD4i) antibodies (MAbs) was analyzed in comparison to parental SF162. Sequence analysis revealed that the P3 major and minor variant Envs contained 14 and 17 amino acid changes, respectively, compared with SF162. The rank order of entry mediated by the three envelopes was P3 major > SF162 > P3 minor, whereas the reverse order was observed for susceptibility to neutralization by CD4i MAbs. Since CD4i epitopes overlap the coreceptor (CoR) binding site, these findings suggest that the amino acid changes accumulated upon in vivo passage of SHIVSF162 result in Env gp120 structural rearrangements that modulate the exposure and/or conformation of the CoR binding site. This, in turn, led to increased entry and infectivity of the P3 major variant and may be responsible, in part, for the enhanced pathogenicity of SHIVSF162P3.
引用
收藏
页码:211 / 217
页数:7
相关论文
共 30 条
[1]   RAPID DEVELOPMENT OF ISOLATE-SPECIFIC NEUTRALIZING ANTIBODIES AFTER PRIMARY HIV-1 INFECTION AND CONSEQUENT EMERGENCE OF VIRUS VARIANTS WHICH RESIST NEUTRALIZATION BY AUTOLOGOUS SERA [J].
ALBERT, J ;
ABRAHAMSSON, B ;
NAGY, K ;
AURELIUS, E ;
GAINES, H ;
NYSTROM, G ;
FENYO, EM .
AIDS, 1990, 4 (02) :107-112
[2]   Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions [J].
Cavacini, LA ;
Duval, M ;
Robinson, J ;
Posner, MR .
AIDS, 2002, 16 (18) :2409-2417
[3]   Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2) [J].
Cayabyab, M ;
Karlsson, GB ;
Etemad-Moghadam, BA ;
Hofmann, W ;
Steenbeke, T ;
Halloran, M ;
Fanton, JW ;
Axthelm, MK ;
Letvin, NL ;
Sodroski, JG .
JOURNAL OF VIROLOGY, 1999, 73 (02) :976-984
[4]   Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIVSF33A molecular clones [J].
Chakrabarti, LA ;
Ivanovic, T ;
Cheng-Mayer, C .
JOURNAL OF VIROLOGY, 2002, 76 (04) :1588-1599
[5]   HIV entry and its inhibition [J].
Chan, DC ;
Kim, PS .
CELL, 1998, 93 (05) :681-684
[6]   VIRAL DETERMINANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 T-CELL OR MACROPHAGE TROPISM, CYTOPATHOGENICITY, AND CD4 ANTIGEN MODULATION [J].
CHENGMAYER, C ;
QUIROGA, M ;
TUNG, JW ;
DINA, D ;
LEVY, JA .
JOURNAL OF VIROLOGY, 1990, 64 (09) :4390-4398
[7]   Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor [J].
ChengMayer, C ;
Liu, R ;
Landau, NR ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 1997, 71 (02) :1657-1661
[8]   Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].
Connor, RI ;
Sheridan, KE ;
Ceradini, D ;
Choe, S ;
Landau, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628
[9]   VPR IS REQUIRED FOR EFFICIENT REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN MONONUCLEAR PHAGOCYTES [J].
CONNOR, RI ;
CHEN, BK ;
CHOE, S ;
LANDAU, NR .
VIROLOGY, 1995, 206 (02) :935-944
[10]   Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo [J].
Etemad-Moghadam, B ;
Sun, Y ;
Nicholson, EK ;
Fernandes, M ;
Liou, K ;
Gomila, R ;
Lee, J ;
Sodroski, J .
JOURNAL OF VIROLOGY, 2000, 74 (09) :4433-4440